1.
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metast...
2.
3.
4.
5.
CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease